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a b s t r a c t
Mastocytosis refers to a group of disorders characterized by the inﬁltration of clonally
derived mast cells to the skin or extracutaneous tissues resulting in a heterogeneous clinical
picture. It is a rare hematologic disorder in all its forms. The exact incidence is unknown;
it affects patients of any age and males and females equally. Its molecular pathogenesis
is incompletely understood. The clinical features of mastocytosis result from both chronic
and episodic mast cell mediator release, signs and symptoms arising from diffuse or focal
tissue inﬁltration, and, occasionally, the presence of an associated non-mast cell clonal
hematologic disease. The histopathologic analysis is essential for deﬁnitive diagnosis but
there is no curative treatment. The authors report a clinical case of a 72-year-old woman
withnohistory of allergies,with bicytopenia,weight loss, anddiffuse axial osteolytic lesions.
This is a rare clinical case of aggressive systemicmastocytosis forwhich palliative treatment
can improve survival and quality of life. A brief review of the literature about this pathology
is also included.
© 2014 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
A 72-year-old Caucasian woman with a history of diverticu-Introduction
Mastocytosis refers to a group of myeloproliferative disorders
characterized by an excessive proliferation of mast cells and
their accumulation in one ormultiple tissues. According to the
World Health Organization (WHO), the disease can be classi-
ﬁed as cutaneous mastocytosis (CM), which describes forms
of mastocytosis that are limited to the skin, and systemic
mastocytosis (SM) in which mast cells inﬁltrate extracu-
taneous organs, with or without skin involvement.1,2 The
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reserved.pathogenesis is not well deﬁned and treatment is only on a
palliative basis.
The authors report a clinical case of SM and brieﬂy review
the literature about this disease.
Clinical caseuesia São José, Hospital Santo António dos Capuchos, 1169-050
losis, surgically-corrected lumbar hernia and plurisegmental
degenerative osteoarticular disease is reported. There was
e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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Figure 1 – Computed tomography scan of the lumbar spine
and sacrum – scattered osteosclerotic lesions on vertebrae,
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Figure 2 – Computed tomography scan of the lumbar spine
and sacrum – osteosclerotic and osteolytic lesions, without
expansive features, spread throughout the axial skeleton
that allowed the classiﬁcation of an aggressive form of SM.
The patient was referred to the Hematology Department
and began chemotherapy with cladribine which gave aacrum and iliac bones (coronal view).
o background of allergies, smoking or alcoholism and she
as taking only analgesic medications. In May 2012, she
as admitted for acute diverticulitis. During her hospital
tay the lower back pain worsened and so a computed
omography (CT) scan of the lumbar spine was performed
hich documented diffuse osteopenia and multiple scattered
steosclerotic lesions on vertebrae, the sacrum and the iliac
ones (Figure 1). After discharge and with a presumptive diag-
osis of occult neoplastic disorder, she was referred to her
octor for further studies.
Several medical tests were performed including blood
nalysis, endoscopic and imaging exams but none showed
elevant changes. In September she started with persistent
iaphoresis with no fever or any symptoms suggestive of an
nfectious focus, anorexia and a quantiﬁed weight loss. The
lood tests revealed slightly elevated levels of alkaline phos-
hatase (162U/L) and lactate dehydrogenase (LDH – 454U/L).
he was admitted again and a CT body scan was performed
Figure 2) which showed osteolytic lesions, in addition to the
iffuse osteosclerotic lesions previously documented, with-
ut expansive features, spread throughout the axial skeleton,
hat were assumed to be bone marrow sclerosis phenomena.
iaphoresis was associated to a pharmacological iatrogenic
ffect and the weight loss to a reactive depression. She was
ischarged and referred to our Internal Medicine Department.
The sequential control blood tests showed increasing
evels of bicytopenia (hemoglobin 11.2 g/dL and platelet count
22×109/L), leukocytosis (19.40 x 109/L), with no formula
nversion, and LDH (572U/L). With strong suspicion of a
ematological disorder, a blood smear, myelogram and bone
arrow biopsy were performed but all were unrevealing. The
mmunological study was negative and Paget’s disease and
ultiple myeloma were excluded. Finally, a percutaneous L1
iopsy was performed. This was essential for the deﬁnitive
iagnosis because it documented a multifocal inﬁltration
f atypical mast cells, characterized by spindle-shaped
nd hypogranular forms, representing 5% of cellularity
nd forming cellular aggregates of more than 15 cells. An
mmunohistochemistry study identiﬁed positive staining
or CD117 and tryptase of these mast cells conﬁrming the
iagnosis of SM (Figures 3–5). These features associated with
eripheral blood test abnormalities (bicytopenia), weight loss(sagittal view).
and presence of osteolytic lesions are sufﬁcient C ﬁndingsFigure 3 – Hematoxylin-eosin stain (magniﬁcation: 400×) –
peripheral ﬁbrosis and atypical mast cells with fusiform
shape (circle).
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Figure 4 – Positive staining for CD117 (magniﬁcation: 400×)
Figure 5 – Positive staining for tryptase of mast cellsidentifying atypical mast cells with fusiform shape.
partial response. Five cycles have been performed so far with
clinical improvement. The patient remains under clinical and
laboratory surveillance.
Discussion
Mastocytosis is a disorder characterized by an excessive pro-
liferation of atypical mast cells and their accumulation in
tissues. This inﬁltration can be limited to the skin (CM) or
involve extracutaneous organs (SM).1,2
This is a rare disease in all its forms. The exact incidence is
unknown and it can appear at any age, but mostly in children
in which the disease is generally limited to the skin; it affects
males and females equally.3
The molecular pathogenesis is incompletely understood
but it is believed that activating mutations in the c-KIT recep-
tor or CD117, essential for normal development and expansion
of mast cells from hematopoietic progenitors, leads to a clonal
hyperproliferation of atypicalmast cells. TheAsp816Valmuta-
tion is the most common.4,5
The clinical features result from both chronic and episodic
mast cell mediator release associated with allergic and
anaphylactic reactions, focal or diffuse tissue inﬁltration by
mast cells and occasionally the presence of an associated
non-mast cell clonal hematologic disease. Urticaria pigmen-
tosa or cutaneous mastocytomas can appear in the CM form,
while SM may present signs and symptoms resulting from
the inﬁltration of mast cells in speciﬁc organs. The most
commonly affected organ systems are the bone marrow,
gastrointestinal tract, lymph nodes, liver, spleen, skeletal
system and genitourinary tract, leading to the following
clinical manifestations: anemia and thrombocytopenia, hep-
atosplenomegaly, portal hypertension and hypersplenism,
malabsorption, lytic bone lesions and pathologic fractures.6,7
The diagnosis is histopathological and should include a
bone marrow evaluation because, in most cases, inﬁltration
occurs. The histological exam is characterized by tissue inﬁl-
tration by atypical mast cells with a spindle or fusiform shape
and a high nucleus:cytoplasm ratio; immunohistochemical
staining with antibodies positive for tryptase, CD117, CD2 and
CD25, and possible detection of mutations of the c-KIT recep-
tor by cytogenetic analysis which is available in the United(magniﬁcation: 400×). CD117 is not speciﬁc so this analysis
is essential to deﬁnitive diagnosis.
States and some academic centers. This study may be supple-
mented with serum tryptase levels and the measurement of
metabolites of mast cell activation, including a 24-hour urine
test for N-methyl histamine and 11-beta-prostaglandine F2.7–9
According to the WHO, diagnostic criteria for CM include
skin lesions with compatible biopsy results, while for SM the
presence of one major (multifocal clusters greater than 15
mast cells) and one minor criterion or three minor criteria
(atypical morphology or spindle shapes in greater than 25%
of the mast cells, c-KIT gene mutation, mast cells expressing
the CD2 or CD25 surfacemarkers or both, and increased serum
tryptase levels greater than 20ng/mL) are required.9
After establishing the diagnosis it is necessary to deﬁne the
disease category and thepresence of B ﬁndings, corresponding
to organ enlargementwithout organ dysfunction, or C ﬁndings
that denote organ function impairment due to excessive mast
cell inﬁltration; this latter is associated to a poorer prognosis.
Our patient found herself inserted in a category of aggressive
SM presenting three C ﬁndings (hematopoietic dysfunction
with bicytopenia, diffuse bone lesions and weight loss due to
malabsorption).7–9
The differential diagnosis is important to exclude other
pathologies such as angioedema, carcinoid syndrome,
pheochromocytoma, metastatic bone disease, myeloprolife-
rative variant of hypereosinophilic syndrome and reactive
mastocytosis which can be seen in patients with solid tumors
and lymphomas.8
Currently, there are no curative therapies for SM and treat-
ment is intended to reduce symptoms and improve quality
of life. Patients with aggressive SM are candidates for mast
cell cytoreductive therapies if C ﬁndings are present. The
most frequently administered therapies are cladribine (1st line
treatment), IFN-2b, glucocorticoids, hydroxyurea and tyro-
sine kinase inhibitors. The choice of cladribine was made
based on the current recommendations for slowly progressive
cases.7,10
The response to treatment is commonly transient andmost
patients eventually relapse. Bone marrow suppression is the
main side effect, as happened to our patient.10
The prognosis of aggressive SM is variable, with some
patients experiencing a rapidly declining course over one to
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wo years, while others follow a slower course with several
ears of survival.
onclusion
his is a rare disease that required perseverance in the diag-
ostic search. The clinical and laboratory ﬁndings can be
uggestive, but bonemarrowbiopsy andmyelogramare essen-
ial for deﬁnitive diagnosis. Although there is no speciﬁc
reatment, chemotherapy may increase survival and improve
uality of life.
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